An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Review found that cytochrome P450 pharmacogenetic testing in adults entering antipsychotic treatment for schizophrenia may show promise in terms of predicting adverse drug reactions such as tardive dyskinesia but further evidence for clinical effectiveness and cost-effectiveness is required
1 Liverpool Reviews and Implementation Group (LRiG), University of Liverpool, , UK
2 York Health Economics Consortium, University of York, , UK
3 Health Methodology Research Group, School of Community Based Medicine, University of Manchester, , UK
4 Medical Statistics, University of Liverpool, , UK
5 The Hesketh Centre, Merseyside NHS Trust, Southport, UK
6 Department of Pharmacology and Therapeutics, University of Liverpool, , UK
7 North Devon District Hospital, Barnstaple, UK
* Corresponding author Email: Nigel.Fleeman@liverpool.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document